LONDON (Thomson Financial) – Pfizer Inc said it has ended trials of PF-3512676 in combination with cytotoxic chemotherapy as a treatment for lung cancer.The company said this includes two Phase 3 and two Phase 2 clinical trials.Pfizer said an interim analysis of the Phase 3 trials by an independent data safety monitoring committee (DSMC) showed there was no evidence that PF-3512676 produced additional clinical efficacy over that achieved with the standard cytotoxic chemotherapy regimen alone.’The DSMC concluded that the risk-benefit profile did not justify continuation of the trials,’ the company said.Pfizer said it licensed PF-3512676 from Coley Pharmaceutical Group Inc in 2005.tf.TFN-Europe_newsdesk@thomson.comwjCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.